SEC Filing Summary for Addex Therapeutics Ltd.

This filing details significant transactions by Timothy Mark Dyer, CEO of Addex Therapeutics Ltd., on September 2, 2026. Dyer exercised and repriced stock options, acquiring and disposing of 3,369,796 options with a repriced strike price of $0.032. Additionally, Dyer acquired and disposed of 16,413,787 shares of common stock, with the strike price for options related to these shares reduced to $0.032. These transactions, particularly the option repricing and exercise, were executed under specific rules (Rule 16b-6(d) and Rule 16b-3) and involved currency conversions from CHF to USD. Post-transaction, Dyer holds 435,192 shares directly and 3,369,796 shares indirectly through options.